Prevention of Recurrent Episodes of Depression With Venlafaxine ER in a 1-Year Maintenance Phase From the PREVENT Study
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To test the long-term efficacy and safety of venlafaxine extended-release (ER) in preventing recurrence in patients with major depression. METHOD: This multiple-phase study, entitled "Prevention of Recurrent Episodes of Depression With Venlafaxine for Two Years" (PREVENT), was conducted from December 2000 through July 2005 in patients with recurrent unipolar depression (DSM-IV) who were initially randomly assigned to double-blind treatment with venlafaxine ER (75 mg/day to 300 mg/day) or fluoxetine (20 mg/day to 60 mg/day) for 10 weeks of acute treatment. Responders then received 6 months of continuation treatment. Those who remained responders were then enrolled into a 12-month maintenance period. Venlafaxine ER responders were randomly assigned to receive double-blind treatment with venlafaxine ER or placebo. Fluoxetine responders were not randomly assigned but continued taking fluoxetine in order to maintain the blind during the maintenance study. Time to recurrence of depression (17-item Hamilton Rating Scale for Depression total score > 12 and < 50% reduction from acute phase baseline) with venlafaxine ER versus that of placebo were compared. RESULTS: The efficacy evaluable sample consisted of 129 patients in each group. The mean daily dose of venlafaxine ER was 224.7 mg (SD = 66.7). The cumulative probability of recurrence through 12 months, based on the primary definition, was 23.1% (95% CI = 15.3 to 30.9) for venlafaxine ER and 42.0% (95% CI = 31.8 to 52.2) for placebo (p = .005, log-rank test). CONCLUSION: Patients who had been successfully treated with venlafaxine ER during acute and continuation therapy were significantly less likely to experience recurrence with venlafaxine ER than with placebo over a 12-month maintenance treatment period. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov identifier NCT00046020.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Kocsis 2007 (n = 336) reported that one participant in the continuation group experienced suicidal thoughts; study authors considered this not related to treatment.”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Kocsis 2007
In the citing paper
“No suicide attempts during the trial were reported.”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Kocsis 2007
In the citing paper
“Suicidal ideations were also reported by one participant in the discontinuation group.”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Kocsis 2007
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
(1976) · Medical Entomology and Zoology · Cited by 8,899
(1993) · PubMed · Cited by 1,900
Assessment of social adjustment by patient self report.
Weissman, M. M. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770090101010 · Cited by 1,782
Keller, M. B. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800180050009 · Cited by 1,643
Self-citationThree-Year Outcomes for Maintenance Therapies in Recurrent Depression
Frank, E. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810240013002 · Cited by 1,297
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945
The inventory for depressive symptomatology (IDS): Preliminary findings
John Rush, A., Giles, D. E., Schlesser, M. A., Fulton, C. L., Weissenburger, J., & Burns, C. (1986) · Psychiatry Research · doi:10.1016/0165-1781(86)90060-0 · Cited by 918
Anderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
Recurrence after recovery from major depressive disorder during 15 years of observational follow-up
Mueller, T. I., Leon, A. C., Keller, M. B., Solomon, D. A., Endicott, J., Coryell, W., Warshaw, M., & Maser, J. D. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.7.1000 · Cited by 897
Self-citationMultiple recurrences of major depressive disorder
Solomon, D. A., Keller, M. B., Leon, A. C., Mueller, T. I., Lavori, P. W., Shea, M. T., Coryell, W., Warshaw, M., Turvey, C., Maser, J. D., et al. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.2.229 · Cited by 835
Self-citationRecognition and management of depression in general practice: consensus statement
Paykel, E. S., & Priest, R. G. (1992) · BMJ · doi:10.1136/bmj.305.6863.1198 · Cited by 540
Judd, L. L., Paulus, M. J., Schettler, P. J., Akiskal, H. S., Endicott, J., Leon, A. C., Maser, J. D., Mueller, T., Solomon, D. A., & Keller, M. B. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.9.1501 · Cited by 458
Self-citationAssessing Anhedonia in Psychiatric Patients: The Pleasure Scale
Fawcett, J. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790010081010 · Cited by 422
Keller, M. B., & Boland, R. J. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00110-3 · Cited by 281 · cited 1×
“Exclusion criteria. Patients who had failed an adequate trial of fluoxetine, venlafaxine, or venlafaxine ER during the current episode of major depression or those who were treatment-resistant (i.e., had failed [1] ≥ 3 previous adequate trials of at least 2 classes of antidepressant medication, or [2] electroconvulsiv…”
BackgroundSelf-citationRelapse in Major Depressive Disorder: Analysis With the Life Table
Keller, M. B. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290080031005 · Cited by 260
Self-citationRush, A. J. (1993) · Medical Entomology and Zoology · Cited by 250
Recovery From Major Depression: A 10-Year Prospective Follow-up Across Multiple Episodes
Solomon, D. A. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830230033005 · Cited by 199
Psychosocial impairment and recurrence of major depression
Solomon, D. A., Leon, A. C., Endicott, J., Mueller, T. I., Coryell, W. H., Shea, M. T., & Keller, M. B. (2004) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2004.07.002 · Cited by 134
Self-citationDiduch, M., Milovac, R., & Thomas, C. (2017) · PharmacotherapyFirst: A Multimedia Learning Resource · doi:10.21019/pharmacotherapyfirst.mdd_overview · Cited by 122
Methodologic issues in maintenance therapy clinical trials
Greenhouse, J. B. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810280029004 · Cited by 89
Depression: A Long-Term Illness
Keller, M. B. (1994) · British Journal of Psychiatry · doi:10.1192/s0007125000293239 · Cited by 87
Self-citationHochstrasser, B., Isaksen, P. M., Koponen, H., Lauritzen, L., Mahnert, F. A., Rouillon, F., Wade, A. G., Andersen, M., Pedersen, S. F., De Swart, J. C. G., et al. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.4.304 · Cited by 85
Lépine, J.-P., Caillard, V., Bisserbe, J.-C., Troy, S., Hotton, J.-M., Boyer, P., & For the PREVERS Investigators (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.836 · Cited by 83
The long-term treatment of depression.
Keller, M. B. (1999) · PubMed · Cited by 75
Self-citationVenlafaxine Versus Placebo in the Preventive Treatment of Recurrent Major Depression
Montgomery, S. A., Entsuah, R., Hackett, D., Kunz, N. R., Rudolph, R. L., & Venlafaxine 335 Study Group (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0307 · Cited by 69
Long-term treatment of recurrent and chronic depression.
Keller, M. B. (2001) · PubMed · Cited by 66
Self-citationFluoxetine in the Prevention of Depressive Recurrences: A Double-Blind Study
Gilaberte, I., Montejo, A. L., de la Gandara, J., Perez-Sola, V., Bernardo, M., Massana, J., Martin-Santos, R., Santiso, A., Noguera, R., Casais, L., et al. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200108000-00009 · Cited by 58
Initial 6-month follow-up of patients with major depressive disorder
Shapiro, R. W., & Keller, M. B. (1981) · Journal of Affective Disorders · doi:10.1016/0165-0327(81)90023-9 · Cited by 56
Self-citationDawson, R., Lavori, P. W., Coryell, W. H., Endicott, J., & Keller, M. B. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(97)00181-x · Cited by 54 · cited 1×
“, had failed [1] ≥ 3 previous adequate trials of at least 2 classes of antidepressant medication, or [2] electroconvulsive therapy, or [3] 2 adequate trials of psychotherapy for mood disorder in the past 3 years) were not eligible to participate.”
Self-citationMilnacipran efficacy in the prevention of recurrent depression: a 12-month placebo-controlled study
Rouillon, F., Warner, B., Pezous, N., & Bisserbe, J. C. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015030-00002 · Cited by 47
Keller, M. B., & Hanks, D. L. (1994) · PubMed · Cited by 31
Self-citation
Cited by
PRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder
Gelenberg, A. J., Freeman, P. B., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H., & Rhoads, R. S. (2010) · Cited by 1,510
Self-citationFluoxetine versus other types of pharmacotherapy for depression
Magni, L. R., Purgato, M., Gastaldon, C., Papola, D., Furukawa, T. A., Cipriani, A., & Barbui, C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004185.pub3 · Cited by 252
Sim, K., Lau, W. K., Sim, J., Sum, M. Y., & Baldessarini, R. J. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv076 · Cited by 218
“, 2005, 2009) than with pharmacotherapies (Montgomery and Dunbar, 1993; M Fava et al., 1998; Lepine et al., 2004; Keller et al., 2007a; 2007b; Kocsis et al., 2007; Kuyken et al., 2008; Bondolfi et al., 2010; Kelin et al., 2010; Mathew et al., 2010; Thase et al., 2011).”
BackgroundLi, C.-T., Lin, C.-P., Chou, K.-H., Chen, I.-Y., Hsieh, J.-C., Wu, C.-L., Lin, W.-C., & Su, T.-P. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2009.11.021 · Cited by 213
“This is why remission without residual symptoms, rather than a 50% improvement on a depression rating scale, is now regarded as an optimal outcome in treating depression (Bakish, 2001; Israel, 2006; Kocsis et al., 2007).”
Bauer, M., Severus, E., Köhler, S., Whybrow, P. C., Angst, J., Möller, H.-J., & on behalf of the Wfsbp Task Force on Treatment Guidelines for Unipolar Depressive Disorders (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2014.1001786 · Cited by 199
“Fluoxetine responders were not randomly assigned but continued taking fl uoxetine in order to maintain the blind during the maintenance study (Kocsis et al. 2007).”
Background
Metadata
- Authors
- Kocsis, J. H., Thase, M. E., Trivedi, M. H., Shelton, R. C., Kornstein, S. G., Nemeroff, C. B., Friedman, E. S., Gelenberg, A. J., Dunner, D. L., Hirschfeld, R. M. A., Rothschild, A. J., Ferguson, J. M., Schatzberg, A. F., Zajecka, J. M., Pedersen, R. D., Yan, B., Ahmed, S., Musgnung, J., Ninan, P. T., & Keller, M. B.
- Affiliations
- Cornell University (US)
- University of Pennsylvania (US)
- The University of Texas Southwestern Medical Center (US)
- Vanderbilt University (US)
- Virginia Commonwealth University (US)
- Emory University (US)
- University of Pittsburgh (US)
- University of Arizona (US)
- The University of Texas Medical Branch at Galveston (US)
- University of Massachusetts Chan Medical School (US)
- University of Utah (US)
- Stanford University (US)
- Rush University (US)
- Pfizer (United States) (US)
- Brown University (US)
- ORCID
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2007-07-15
- Volume
- 68
- Issue
- 07
- Pages
- 1014-1023
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2073228294
- Semantic Scholar
- 8dc9020e6c71f6bbcf5739a447273d8974bdfed8
- Cited by
- 67
- References
- 33
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 5 · 2022: 3 · 2021: 2 · 2020: 2 · 2018: 1 · 2017: 2 · 2016: 1 · 2015: 9 · 2014: 1 · 2013: 4 · 2012: 3
- FWCI
- 5.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- eScholarship@UMassChan (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- venlafaxine extended release, depression recurrence prevention, major depressive disorder, maintenance therapy, fluoxetine, antidepressant efficacy, long-term safety, PREVENT study
- MeSH terms
- Venlafaxine Hydrochloride, Adult, Cyclohexanols, Delayed-Action Preparations, Major Depressive Disorder, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Outpatients, Selective Serotonin Reuptake Inhibitors, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.